What the July FDA Peptide Vote Actually Changed (and What It Didn’t)

On July 23 and 24, an FDA advisory committee did something people who follow this closely did not expect. It recommended six of seven peptides for the compounding list — over the written objections of the agency’s own scientists, who had recommended against all seven.

Reports from the room described an audible gasp when the first tally was read. This panel had rarely, if ever, voted against FDA staff’s written recommendation.

It was a real event. It is also being described online in ways that are simply wrong, and the errors are the kind that cost people money. So here is what happened.

What was actually voted on

The Pharmacy Compounding Advisory Committee considered seven peptides for the 503A Bulks List — the roster of substances that compounding pharmacies may prepare against an individual prescription.

The results, each voted separately in free base and acetate forms:

• BPC-157 — recommended, 8–6 with one abstention (reviewed for ulcerative colitis)
• KPV — recommended, 8–6 with one abstention (wound healing and inflammatory conditions)
• TB-500 — recommended, 8–6 with one abstention (wound healing)
• MOTS-c — recommended, 7–5 with two abstentions (obesity and osteoporosis)
• Semax — recommended, 8–5 with one abstention (selected neurologic uses)
• Epitalon — recommended (insomnia)
• Emideltide, better known as DSIP — rejected, the only one

Look at those margins. Not one was a landslide. Every vote carried abstentions. This was a genuinely divided panel, and that matters when you read someone describing it as vindication.

The three separate legal events people keep collapsing into one

This is the part worth getting right, because almost every confused conversation traces back to it.

Event one: removal from Category 2. On April 15, 2026, twelve peptides came off the FDA’s Category 2 restricted list, largely because the nominations were withdrawn. That group included BPC-157, TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax, PEG-MGF, DSIP, Epitalon, KPV, LL-37, and DiHexa. Removal from a prohibition list is not permission. It removes a barrier; it does not open a door.

Event two: the July advisory vote. A recommendation. Non-binding. The FDA is free to disagree with it, and the Secretary of Health and Human Services would still need to formally approve any additions.

Event three: actual placement on the list. This requires formal rulemaking — a proposed rule, a public comment period, and a final rule. That process realistically runs into 2027 and beyond.

Nothing became legal to compound in July that was not legal in June. Six recommendations, zero changes to what a pharmacy can dispense today.

Why the panel overruling FDA scientists matters both ways

I find this genuinely interesting, and I do not think it means what either side is claiming.

The FDA’s career scientists opposed all seven, citing thin human trial data along with unresolved questions about impurity and immunogenicity. Those are not made-up concerns. Most of these compounds have substantial animal literature and essentially no human trials, which is exactly what I have written about each of them individually.

The panel — which included representatives from industry, academia, state government, pharmacy boards, and clinical practice — disagreed. Reasonable people can look at the same evidence base and weigh access against uncertainty differently.

What I would resist is treating the vote as proof these compounds work. It is a recommendation about whether pharmacies should be permitted to prepare them for individual patients under prescription. That is a question about regulatory pathways, not about efficacy. A peptide does not become better supported because a committee voted 8–6.

What this means if you are considering peptides

Availability may change, in either direction. If rulemaking proceeds, more compounds become legitimately available through licensed pharmacies. If it stalls, the current situation persists. Either way, nothing about your options changed this summer.

Be very cautious with anyone marketing on this news. “FDA-approved” is not what happened. Nor is “now legal.” Any seller using that language is either misinformed or counting on you being misinformed, and neither is a good sign about the rest of their operation.

The gray market is still the gray market. An enormous online trade sells these compounds labeled “for research use only, not for human consumption.” That disclaimer is the legal architecture that lets them ship. It also means no prescriber, no sterility requirements for injectables, no pharmacist verification, and no recourse if something goes wrong. A certificate of analysis tells you about a tested sample. It tells you nothing about the sterility of the vial in your hand.

Notice which ones weren’t on the docket. Injectable GHK-Cu came off Category 2 in April but was not among the seven reviewed in July. Neither were CJC-1295, Ipamorelin, Sermorelin, Thymosin Alpha-1, or SS-31. Their status is unchanged and unaddressed.

My honest read

I have written in detail about most of these compounds, and my position has not moved. The mechanisms are interesting. The animal data on several is substantial and consistent. The human data is thin to absent. Those three things are all true at once, and a committee vote does not resolve the tension between them.

What the vote does suggest is that a regulated pathway may eventually exist — which, whatever you think of the compounds, is better than tens of thousands of people injecting unregulated product they ordered online. Supervision, screening, and pharmacy-grade sterility are improvements even when the underlying evidence stays uncertain.

In the meantime, the advice I would give has not changed: get your hormones, thyroid, ferritin, and metabolic markers actually assessed first. A peptide layered on top of an unaddressed foundation is an expensive way to not solve the problem.

Frequently Asked Questions

Does this mean BPC-157 is now legal?

No. The vote was a non-binding recommendation. Formal rulemaking must happen before anything changes, and that realistically runs into 2027.

Why was DSIP the only rejection?

The panel weighed each compound separately on its own evidence and safety profile. DSIP fell short by a single-vote margin, which reflects how divided the committee was overall rather than a clear verdict.

Are these peptides FDA-approved now?

No, and this is the most common misunderstanding. The 503A Bulks List governs what compounding pharmacies may prepare from bulk substances. It is an entirely different thing from drug approval.

What about GHK-Cu, CJC-1295, or the others I’ve read about?

Injectable GHK-Cu came off Category 2 in April but was not part of the July review. Several others were never on either list. Their status is simply unchanged.